{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:58Z","timestamp":1791661918213,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Optometry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.optom.2026.100635","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:54:36Z","timestamp":1791604476000},"page":"100635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine for myopia control: Two-year randomised trial in children from Central Europe"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-9908","authenticated-orcid":false,"given":"Emilia","family":"Wn\u0119kowicz-Augustyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wyl\u0119ga\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5589-4249","authenticated-orcid":false,"given":"Martyna","family":"Kobielnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-8880","authenticated-orcid":false,"given":"S\u0142awomir","family":"Teper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.optom.2026.100635_bib0001","article-title":"Diagnostic challenges in high myopia: identification of sight-threatening complications and the role of artificial intelligence","volume":"5","author":"He","year":"2025","journal-title":"Front Ophthalmol"},{"key":"10.1016\/j.optom.2026.100635_bib0002","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ajo.2025.06.034","article-title":"Factors affecting the lifetime cost of myopia and the impact of active myopia treatments in Europe","volume":"278","author":"Lee","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.optom.2026.100635_bib0003","article-title":"Myopia development: multifactorial interplay, molecular mechanisms and possible strategies","volume":"12","author":"Morgan","year":"2025","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.optom.2026.100635_bib0004","first-page":"599","article-title":"Risk factors for myopia among children and adolescents: an umbrella review","volume":"107","author":"Huang","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"14","key":"10.1016\/j.optom.2026.100635_bib0005","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/s41433-025-03949-1","article-title":"Current and emerging strategies for myopia control: a narrative review of optical, pharmacological, behavioural, and adjunctive therapies","volume":"39","author":"Maulvi","year":"2025","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.optom.2026.100635_bib0006","doi-asserted-by":"crossref","first-page":"M106","DOI":"10.1167\/iovs.18-25958","article-title":"IMI - Interventions Myopia Institute: interventions for Controlling Myopia Onset and Progression Report","volume":"60","author":"Wildsoet","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.optom.2026.100635_bib0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.18240\/ijo.2025.04.20","article-title":"Myopia control efficacy of peripheral defocus modifying spectacle lenses in children and adolescents: a Meta-analysis","volume":"18","author":"Fan","year":"2025","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.optom.2026.100635_bib0008","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","article-title":"Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial","volume":"104","author":"Lam","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.optom.2026.100635_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2025-002329","article-title":"Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine for myopia control: a randomised trial in children from Central Europe","volume":"10","author":"Wn\u0119kowicz-Augustyn","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"10.1016\/j.optom.2026.100635_bib0021","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/aos.13603","article-title":"Axial length growth and the risk of developing myopia in European children","volume":"96","author":"Tideman","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.optom.2026.100635_bib0010","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1038\/s41598-023-32700-7","article-title":"Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years","volume":"13","author":"Lam","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.optom.2026.100635_bib0011","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: phase 2 Report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.optom.2026.100635_bib0012","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.66.12.39","article-title":"IMI\u2014interventions for controlling myopia onset and progression 2025","volume":"66","author":"Bullimore","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.optom.2026.100635_bib0013","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1167\/iovs.10-5457","article-title":"Human Optical Axial Length and Defocus","volume":"51","author":"Read","year":"2010","journal-title":"Investigative Opthalmol Visual Sci"},{"issue":"6","key":"10.1016\/j.optom.2026.100635_bib0014","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/cxo.12312","article-title":"Animal models in myopia research","volume":"98","author":"Schaeffel","year":"2015","journal-title":"Clin Exp Optom"},{"issue":"4","key":"10.1016\/j.optom.2026.100635_bib0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neuron.2004.08.008","article-title":"Homeostasis of Eye Growth and the Question of Myopia","volume":"43","author":"Wallman","year":"2004","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.optom.2026.100635_bib0016","doi-asserted-by":"crossref","first-page":"M31","DOI":"10.1167\/iovs.18-25967","article-title":"IMI \u2013 report on experimental models of emmetropization and myopia","volume":"60","author":"Troilo","year":"2019","journal-title":"Investigative Opthalmol Visual Sci"},{"issue":"1","key":"10.1016\/j.optom.2026.100635_bib0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.optom.2026.100635_bib0018","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"30","key":"10.1016\/j.optom.2026.100635_bib0019","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1721443115","article-title":"Scleral hypoxia is a target for myopia control","volume":"115","author":"Wu","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.optom.2026.100635_bib0020","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0883073814538666","article-title":"Role of the dopaminergic system in the development of myopia in children and adolescents","volume":"29","author":"Nebbioso","year":"2014","journal-title":"J Child Neurol"}],"container-title":["Journal of Optometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888429626000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888429626000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:44:18Z","timestamp":1791661458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888429626000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"alternative-id":["S1888429626000294"],"URL":"https:\/\/doi.org\/10.1016\/j.optom.2026.100635","relation":{},"ISSN":["1888-4296"],"issn-type":[{"value":"1888-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine for myopia control: Two-year randomised trial in children from Central Europe","name":"articletitle","label":"Article Title"},{"value":"Journal of Optometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.optom.2026.100635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Spanish General Council of Optometry.","name":"copyright","label":"Copyright"}],"article-number":"100635"}}